Estrogen Receptors in Human Pituitary Tumors

Abstract

The relationship between the presence of estrogen receptors in pituitary adenomas and the post surgical evolution of the patients in order to find another prognostic parameter for these tumors have been studied to improve the treatment selection. Estrogen receptors were studied by immunocytochemistry in histological sections of paraffin embedded 42 pituitary adenomas. Only 19% of these tumors were positive for estrogen receptors. As expected, the higher concentration (60%) was found in prolactin secreting adenomas, although we found estrogen receptors in one somatotroph and in one nonsecreting. The most aggressive tumors were those negative for estrogen receptors within the prolactinomas and the positive somatotrophinoma. The results of this work suggest that the determination of estrogen receptors in pituitary tumors might help as a prognostic factor in these adenomas.

Key words

pituitary - adenomas - estrogen receptor - prognosis

References

• 1 Gruber CG, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens.  N Engl J Med. 2002;  346 340-352
• 2 Machiavelli GA, Rivolta CM, Artese R, Basso A, Burdman JA. Expression of c-myc and c-fos and binding sites for estradiol and progesterone in human pituitary tumors.  Neurol Res. 1998;  20 709-712
• 3 Zafar M, Ezzai S, Raymyar L, Pan N, Smyth HS, Asa SL. Cell-specific expression of estrogen receptor in the human pituitary and its adenomas.  J Clin Endocrinol Metab. 1995;  80 3621-3627
• 4 Shupnik MA, Pitt LK, Soh AY, Anderson A, Lopes MB, Laws Jr ER. Selective expression of estrogen receptor á and â isoforms in human pituitary tumors.  J Clin Endocrinol Metab. 1998;  83 3965-3972
• 5 Kalbermann LE, Machiavelli GA, Nicola AF De, Weissenberg LS, Burdman JA. Synthesis of DNA in oestrogen-induced pituitary tumours in rats: Effect of bromocriptine.  J Endocr. 1980;  87 221-225
• 6 MacGregor AM, Scanlon MF, Hall R, Hall K. Effects of bromocriptine on pituitary tumor size.  Brit Med J. 1979;  11 700-703
• 7 Knight WA, Livingston RB, Gregory EJ, MacGuire WL. Estrogen receptor as an independent prognostic factor for early recurrences in breast cancer.  Cancer Res. 1997;  37 4669-4671
• 8 Jensen EV, Block GE, Smith S, Kyser K, Sombre ER De. Estrogen receptors and breast cancer response to adrenalectomy.  NCI Monographs. 1971;  34 55-70
• 9 Mac Gregor JI, Jordan BC. Basic guide to the mechanism of antiestrogen action.  Phrmacol Rev. 1998;  50 151-196
• 10 Szijan I, Burdman JA, Alonso GE. Effects of dopamine agonists and antagonists on the binding of (3H)-estradiol to its receptors in the anterior pituitary gland of male rats.  Endocrinology. 1985;  117 1748-1757
• 11 Kaldjian EP, Long J, Robertson D, Davenport R. et al . Immunohistochemical analysis of hormone receptors, tumor vascularity and proliferative activity in paraffin-embedded sections of breast carcinoma tissues.  Immunohistochem. 1993;  1 31-38
• 12 Niall HD, Hogan ML, Sauer R. Sequences of pituitary and placental lactogenic and growth hormones: evolution from a primordial peptide by gene reduplication.  Proc Natl Acad Sci USA. 1971;  68 866-870
• 13 Pernicone PJ, Scheithauer BW, Horuath E. et al .Pituitary and Sellar Region. In: Strenberg SS (Ed). Histology for pathologist. New York: Raven Press 1992 Chap. 13: 279-299
• 14 Burdman JA, Guerra LN, Calabrese MT, Basso A. Bromocriptine and the expression of c-myc and c-fos in human prolactinomas.  Neurol Res. 2001;  23 721-723
• 15 Kalberman LE, Szijan I, Burdman JA. Cell proliferation in the rat pituitary gland. A mechanism of control in prolactin cells.  Experientia. 1979;  35 689-690
• 16 Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, Jaquet P, Kordon C, Enjalbert A. Decreased expression of the two D2 dopamine receptors isoforms in bromocriptine-resistant prolactinomas.  Neuroendocrinology. 1994;  60 314-322

Correspondence